Summary
No AI-generated narrative/response text to audit was provided—only a list of claims. As a result, label alignment cannot be verified against the supplied FDA-approved prescribing information in a structured way.
Category Scores
Accurate Statements
Unsupported Statements
Amitiza's generic name is lubiprostone.
Cannot be verified because the input is not an FDA label excerpt providing a claim that Amitiza’s generic name is lubiprostone in the way needed for auditing the specific AI response context.
Lubiprostone is used to treat chronic idiopathic constipation.
Cannot be verified in context (no AI response text/indication phrasing mapped to the provided label excerpts).
Lubiprostone is used to treat opioid-induced constipation.
Cannot be verified in context (no AI response text/indication phrasing mapped to the provided label excerpts, including limitation for diphenylheptane opioids).
Lubiprostone is used to treat irritable bowel syndrome with constipation in adult women.
Cannot be verified in context (no AI response text/indication phrasing mapped to label’s 'women at least 18 years old').
Lubiprostone works by increasing fluid secretion in the intestines.
Cannot be verified as stated against the exact label wording/context without the AI response text; label excerpt indicates enhanced chloride-rich intestinal fluid secretion (mechanism nuance not verifiable here).
Increasing fluid secretion in the intestines helps to soften stool.
Not directly supported by the provided label excerpts.
Increasing fluid secretion in the intestines helps to stimulate bowel movements.
Not directly supported by the provided label excerpts.
A patent set to expire in 2027 was invalidated by a U.S. District Court in 2017.
This is not supported by the provided FDA label excerpts.
Generic versions of lubiprostone could become available earlier than anticipated.
Not supported by the provided FDA label excerpts.
Lupin Pharmaceuticals received approval from the U.S. Food and Drug Administration (FDA) for its generic lubiprostone capsules.
Not supported by the provided FDA label excerpts.
Common side effects of lubiprostone include nausea.
Cannot be verified in context (no mapping to the AI response text; label indicates nausea as an adverse reaction).
Common side effects of lubiprostone include diarrhea.
Cannot be verified in context (label indicates diarrhea as an adverse reaction, but 'common' is not evidenced by provided excerpts).
Common side effects of lubiprostone include headache.
Not supported by the provided label excerpts (only nausea, diarrhea, syncope/hypotension, dyspnea listed in provided adverse reaction excerpts).
Common side effects of lubiprostone include abdominal pain.
Not supported by the provided label excerpts.
Patients experiencing severe diarrhea or dehydration should consult their doctor.
Label excerpt instructs discontinuation and contact provider if severe diarrhea occurs; 'dehydration' is not included in provided excerpts.
Lubiprostone is a prescription medication.
Not supported by the provided FDA label excerpts.
Lubiprostone's mechanism of action increases intestinal fluid secretion.
Cannot be verified in context; label excerpt states enhances chloride-rich intestinal fluid secretion via ClC-2 activation (nuance not fully verifiable from the claim alone).
Generic versions of lubiprostone must receive approval from regulatory bodies like the U.S. FDA before they can be marketed.
Not supported by the provided FDA label excerpts.
The generic approval process ensures that generic drugs are bioequivalent to their brand-name counterparts.
Not supported by the provided FDA label excerpts.
The generic approval process ensures that generic drugs meet quality standards.
Not supported by the provided FDA label excerpts.
Contradictions
Important Omissions
Contraindication detail (mechanical gastrointestinal obstruction) and related warning requirement to confirm absence of obstruction prior to initiating therapy.
Importance:
Moderate
FDA label adverse reaction/warnings not mentioned in the claims (e.g., syncope/hypotension, dyspnea) and administration instruction to take with food and water; swallow whole without breaking apart or chewing.
Importance:
Moderate
Opioid-induced constipation limitation: effectiveness not established for patients taking diphenylheptane opioids (e.g., methadone).
Importance:
Moderate
Specific dosing regimens by indication (CIC/OIC 24 mcg twice daily; IBS-C 8 mcg twice daily) and hepatic impairment adjustments.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several claims include potentially inaccurate or unsupported adverse effects (e.g., headache, abdominal pain) and omit key safety information from the supplied label (contraindication, syncope/hypotension, dyspnea, mechanical obstruction evaluation, and OIC diphenylheptane opioid limitation).
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Multiple statements are not supported by the provided FDA label excerpts (including headache/abdominal pain, generic regulatory process details, patent/court/generic availability claims) and key label limitations/warnings/dosing/administration details are omitted.
Suggested Improvement
Limit claims strictly to content supported by the provided label excerpts; remove or qualify unsupported statements; include label-supported safety elements (contraindication/mechanical obstruction evaluation, syncope/hypotension, dyspnea) and dosing/administration instructions and OIC limitation.